Literature DB >> 6487463

Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination.

J O Miners, R A Robson, D J Birkett.   

Abstract

The disposition of clofibric acid, a drug metabolised largely by glucuronidation, was studied in eight males, eight females and eight females receiving oral contraceptive steroids (OCS). Clofibric acid plasma clearance was not significantly different in males compared to the control female group but was 48% greater (P less than 0.01) in women receiving OCS compared to non-pill using females. This difference was due to an alteration in clofibric acid metabolic clearance as there were no differences between the groups in clofibric acid free fraction. Along with previous data the results suggest that induction of drug glucuronidation by OCS may be of clinical importance, although any sex-related differences are unlikely to be of clinical significance.

Entities:  

Keywords:  Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--pharmacodynamics; Drugs--men; Drugs--women; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel; Mestranol; Metabolic Effects; Norethynodrel; Oral Contraceptives--pharmacodynamics; Reproductive Control Agents; Treatment

Mesh:

Substances:

Year:  1984        PMID: 6487463      PMCID: PMC1463532          DOI: 10.1111/j.1365-2125.1984.tb02461.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Species variation in the taurine conjugation of clofibric acid [proceedings].

Authors:  J Caldwell; T S Emudianughe; R L Smith
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

2.  UDP-glucuronosyltransferase activities. Guidelines for consistent interim terminology and assay conditions.

Authors:  K W Bock; B Burchell; G J Dutton; O Hänninen; G J Mulder; I S Owens; G Siest; T R Tephly
Journal:  Biochem Pharmacol       Date:  1983-03-15       Impact factor: 5.858

3.  Increased metabolic clearance of acetaminophen with oral contraceptive use.

Authors:  D R Abernethy; M Divoll; H R Ochs; B Ameer; D J Greenblatt
Journal:  Obstet Gynecol       Date:  1982-09       Impact factor: 7.661

4.  Effects of oral contraceptive steroids on acetaminophen metabolism and elimination.

Authors:  M C Mitchell; T Hanew; C G Meredith; S Schenker
Journal:  Clin Pharmacol Ther       Date:  1983-07       Impact factor: 6.875

5.  The simultaneous analysis of clofibric acid and probenecid and the direct analysis of clofibric acid glucuronide by high-performance liquid chromatography.

Authors:  J R Veenendaal; P J Meffin
Journal:  J Chromatogr       Date:  1981-04-10

6.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

7.  Probenecid-clofibrate interaction.

Authors:  J R Veenendaal; P M Brooks; P J Meffin
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

8.  Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives.

Authors:  D R Abernethy; D J Greenblatt; H R Ochs; D Weyers; M Divoll; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

9.  Acetaminophen kinetics in the elderly.

Authors:  M Divoll; D R Abernethy; B Ameer; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

10.  Environmental factors affecting paracetamol metabolism in London factory and office workers.

Authors:  J C Mucklow; H S Fraser; C J Bulpitt; C Kahn; G Mould; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

View more
  19 in total

Review 1.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon.

Authors:  H Mönig; C Baese; H T Heidemann; E E Ohnhaus; H M Schulte
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 3.  Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives.

Authors:  Valérie A Damoiseaux; Johannes H Proost; Vincent C R Jiawan; Barbro N Melgert
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin.

Authors:  L O Eriksson; E Wåhlin-Boll; H Liedholm; P Seideman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 6.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

7.  Paracetamol metabolism in pregnancy.

Authors:  J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

8.  Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.

Authors:  J I Macdonald; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 9.  Gender differences in pharmacokinetics.

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

10.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.